This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Bristol-Myers Squibb Company
Drug Names(s): XL413
Description: XL413 is a small molecule inhibitor of the serine-threonine kinase Cdc7. The function of Cdc7 is required for cellular DNA synthesis to proceed, and its activity is often upregulated in cancer cells. Studies suggest that Cdc7 plays a role in regulation of cell cycle checkpoint control, and protects tumor cells from apoptotic cell death during replication stress. Therefore, inhibition of Cdc7 may have utility in the treatment of a wide variety of cancers, either as a single agent or in combination with DNA damaging agents.
Deal Structure: XL413 is being co-developed with Bristol-Myers Squibb Company (BMS), and BMS has primary responsibility for the development and commercialization of the compound. Exelixis exercised its option under its collaboration agreement with BMS to co-develop and co-commercialize XL413 in the United States.
Partners: Exelixis, Inc.
Additional information available to subscribers only: